Northwire Canada EditionWednesday, July 15, 2026
Northwire
EFF 0.030 +20.0% W 0.500 +1.0% RDG 0.160 +0.0% ARIC 0.780 +4.0% VROY 3.44 +5.2% ROCK 3.81 +3.0% APMI 0.120 +0.0% EM 3.58 −4.8% ALS 66.04 +6.8% MEK 0.065 +44.4% TLO 6.00 +13.0% ADE 0.045 −66.7% FAIR 0.060 +33.3% SVRS 0.420 −2.3% RES 0.050 +42.9% CYG 0.120 +0.0% EFF 0.030 +20.0% W 0.500 +1.0% RDG 0.160 +0.0% ARIC 0.780 +4.0% VROY 3.44 +5.2% ROCK 3.81 +3.0% APMI 0.120 +0.0% EM 3.58 −4.8% ALS 66.04 +6.8% MEK 0.065 +44.4% TLO 6.00 +13.0% ADE 0.045 −66.7% FAIR 0.060 +33.3% SVRS 0.420 −2.3% RES 0.050 +42.9% CYG 0.120 +0.0%
M&A / Property

Well Health, Healwell roll out Welltrust

WELL · Price

Executive Summary

  • Well Health Technologies Corp. and Healwell AI Inc. have launched the first phase of "Welltrust," a platform designed to accelerate ethical, AI-powered patient identification for clinical research within Well-operated clinics in Canada.
  • The platform utilizes Healwell’s Darwen AI technology to identify high-fit patients with chronic or complex conditions who have explicitly consented to be contacted about clinical trial opportunities, aiming to improve recruitment rates and trial success probabilities.
  • The initiative establishes a secure, privacy-preserving infrastructure compliant with Canadian privacy laws, allowing patients to voluntarily consent to data usage for research while maintaining their right to decline without affecting their care.

Key Details

  • Platform Name: Welltrust (First Phase Launch).
  • Parties Involved: Well Health Technologies Corp. (WELL/TSX, WHTCF/OTC) and Healwell AI Inc. (AIDX/TSX, HWAIF/OTC).
  • Core Function: Enables secure, consent-driven patient identification for clinical research.
  • Technology: Leverages Healwell’s proprietary "Darwen AI" platform for AI-enabled clinical trial recruitment.
  • Target Population: Patients with chronic or complex conditions who have explicitly consented to be contacted regarding clinical trials.
  • Consent Framework:
    • Patients can consent to their personal health information being used for specific purposes (e.g., clinical trials, information review studies).
    • Participation is voluntary; patients can safely and securely decline participation without impacting their access to care at Well clinics.
  • Governance: Includes a unified privacy, consent, and data-governance layer to meet Canadian privacy and regulatory standards.
  • Future Use Cases: Designed to support real-world evidence generation and enhanced clinical decision support tools as capabilities expand.
  • Market Context: Well operates the largest owned and operated health care ecosystem in Canada with more than 240 clinics, and its solutions power over 43,000 health care providers in the US and Canada.

Notable Quotes

  • Dr. Alexander Dobranowski, President of Healwell AI: "Welltrust embodies our commitment to responsible and impactful AI in health care. By integrating Healwell's data and AI capabilities directly into Well's clinical environment, we are creating an advanced AI-powered ethical patient identification and research acceleration platform. This will accelerate research and patient access to potentially life-saving innovations while respecting high standards of privacy and patient autonomy."
  • Dr. Michael Frankel, Chief Medical Officer of Well Health: "This launch marks a major step forward in our mission to empower patients and improve health care outcomes through the use of technology. Welltrust allows patients to participate in research to accelerate the next generation of therapeutics and diagnostics in a safe, transparent way. Welltrust enables partners in the life sciences ecosystem to work with a scalable, consent-driven data infrastructure. We are proud to formalize this next phase of innovation through our collaboration with Healwell."
Read the original news release →

More from Well Health Technologies Corp